AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citizens Raises Benitec Biopharma's Price Target to $22 Amid Positive Oculopharyngeal Muscular Dystrophy Treatment Results
ByAinvest
Tuesday, Nov 18, 2025 6:26 am ET1min read
Citizens JMP raised Benitec Biopharma Inc.'s (BNTC) price target to $22 from $20, citing positive topline clinical data results for its treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The treatment achieved a 100% response rate in Phase 1b/2a trials, reducing swallowing difficulties and shortening liquid consumption time. The FDA has granted the treatment Fast Track designation. Suvretta Capital Management also invested $20 million in the company.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet